Strategy for the Prediction and Selection of Drug Substance Salt Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategy for the Prediction and Selection of Drug Substance Salt Forms
Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.


Pharmaceutical Technology


2. B.D. Anderson and K.P. Flora, "Preparation of Water-Soluble Compounds Through Salt Formation," in The Practice of Medicinal Chemistry, C.G. Wermuth, Ed. (Academic Press, New York, NY, 1996), pp. 739–754.

3. P.H. Stahl and C.G. Wermuth, Handbook of Pharmaceutical Salts (Wiley-VCH, Weinheim, Germany, 2002.)

4. L.D. Bighley, S.M. Berge, and D.C. Monkhouse, "Salt Forms of Drugs and Absorption," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan JC, Eds. (Marcel Dekker, New York, NY, 1995), pp. 453–499.

5. E.C. Ware and D.R. Lu, "An Automated Approach to Salt Selection for New Unique Trazodone Salts," Pharm. Res. 21 (1), 177–184 (2004).

6. D.A. Haynes, W. Jones, and W.D.S. Motherwell, "Occurrence of Pharmaceutically Acceptable Anions and Cations in the Cambridge Structural Database," J. Pharm. Sci. 94 (10), 2111–2120 (2005).

7. P.L. Gould, "Salt Selection for Basic Drugs," Int. J. Pharm. 33 (1–2), 201–217 (1986).

8. K.R. Morris et al., "An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate," Int. J. Pharm. 105 (2), 209–217 (1994).

9. W-Q. Tong and G. Whitesell, "In Situ Salt Screening—A Useful Technique for Discovery Support and Preformulation Studies," Pharm. Dev. Tech. 3 (2), 215–223 (1998).

10. M. Sacchetti, "General Equations for In Situ Salt Screening of Multibasic Drugs in Multiprotic Acids," Pharm. Dev. Tech. 5 (4), 579–582 (2000).

11. R.J.Bastin, M.J. Bowker, and B.J. Slater, "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities," Org. Proc. Res. Dev. 4 (5), 427–435 (2000).

12. A.T.M. Serajuddin and M. Pudipeddi, "Salt-Selection Strategies," in Handbook of Pharmaceutical Salts, P.H. Stahl and C.G. Wermuth, Eds. (Wiley-VCH, Weinheim, Germany, 2002), pp. 135–160.

13. M.J. Bowker, "A Procedure for Salt Selection and Optimization," in Handbook of Pharmaceutical Salts, P.H. Stahl and C.G. Wermuth, Eds. (Wiley-VCH, Weinheim, Germany, 2002), pp. 161–189.

14. R.B. Hammond et al., "Grid-Based Molecular Modeling for Pharmaceutical Salt Screening: Case Example of 3,4,5,7,8,9-hexahydro-2H-pyrimido-(1,2-a)-primidinium acetate," J. Pharm. Sci. 95 (11), 2361–2372 (2006).

15. Lange's Handbook of Chemistry, J.A. Dean, Ed. (McGraw-Hill, New York, NY, 12th edition, 1979), pp. 5–7.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here